Targets › CD25
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2032.
Open in Phaseline: the race on CD25, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| PolTREG | ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs) Ex vivo expanded regulatory T cell therapy | CD4, CD25, IL2RA | Phase 2 | Presymptomatic Diabetes Type 1 (Stage 1) | Dec 2032 |
Presymptomatic Diabetes Type 1 (Stage 1) (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.